TargetInduced myeloid leukemia cell differentiation protein Mcl-1(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataKi: 0.700nMAssay Description:Inhibition of Mcl1 (unknown origin) by TR-FRET assayMore data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataKi: 0.900nM ΔG°: -51.5kJ/mole IC50: 3.40nMpH: 7.4 T: 2°CAssay Description:TR-FRET assay was used to assess the ability of compounds to disrupt the interaction between recombinant human Mcl-1 and a labeled BIM peptide probe....More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataKi: 1.20nM ΔG°: -50.7kJ/mole IC50: 4.20nMpH: 7.4 T: 2°CAssay Description:TR-FRET assay was used to assess the ability of compounds to disrupt the interaction between recombinant human Mcl-1 and a labeled BIM peptide probe....More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataKi: 1.20nM ΔG°: -50.7kJ/mole IC50: 4.70nMpH: 7.4 T: 2°CAssay Description:TR-FRET assay was used to assess the ability of compounds to disrupt the interaction between recombinant human Mcl-1 and a labeled BIM peptide probe....More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataKi: 1.60nM ΔG°: -50.0kJ/mole IC50: 5.96nMpH: 7.4 T: 2°CAssay Description:TR-FRET assay was used to assess the ability of compounds to disrupt the interaction between recombinant human Mcl-1 and a labeled BIM peptide probe....More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataKi: 16nM ΔG°: -44.3kJ/mole IC50: 59.5nMpH: 7.4 T: 2°CAssay Description:TR-FRET assay was used to assess the ability of compounds to disrupt the interaction between recombinant human Mcl-1 and a labeled BIM peptide probe....More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataKi: 42nMAssay Description:Inhibition of Mcl1 (unknown origin) by TR-FRET assayMore data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataKi: 44nM ΔG°: -41.8kJ/mole IC50: 162nMpH: 7.4 T: 2°CAssay Description:TR-FRET assay was used to assess the ability of compounds to disrupt the interaction between recombinant human Mcl-1 and a labeled BIM peptide probe....More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataKi: 48nMAssay Description:Inhibition of Mcl1 (unknown origin) by TR-FRET assayMore data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataKi: 64nM ΔG°: -40.9kJ/mole IC50: 237nMpH: 7.4 T: 2°CAssay Description:TR-FRET assay was used to assess the ability of compounds to disrupt the interaction between recombinant human Mcl-1 and a labeled BIM peptide probe....More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataKi: 104nM ΔG°: -39.7kJ/mole IC50: 383nMpH: 7.4 T: 2°CAssay Description:TR-FRET assay was used to assess the ability of compounds to disrupt the interaction between recombinant human Mcl-1 and a labeled BIM peptide probe....More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataKi: 155nMAssay Description:Inhibition of Mcl1 (unknown origin) by TR-FRET assayMore data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataKi: 290nMAssay Description:Inhibition of Mcl1 (unknown origin) by TR-FRET assayMore data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataKi: 739nMAssay Description:Inhibition of Mcl1 (unknown origin) by TR-FRET assayMore data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataKi: 1.99E+3nMAssay Description:Inhibition of Mcl1 (unknown origin) by TR-FRET assayMore data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataKi: 4.96E+3nMAssay Description:Inhibition of Mcl1 (unknown origin) by TR-FRET assayMore data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataKi: 4.96E+3nMAssay Description:Inhibition of Mcl1 (unknown origin) by TR-FRET assayMore data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataKi: 5.21E+3nMAssay Description:Inhibition of Mcl1 (unknown origin) by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 0.0800nMAssay Description:Inhibition of SMO-mediated hedgehog signalling pathway in human HPEM cells by luciferase reporter gene assayMore data for this Ligand-Target Pair
Affinity DataIC50: 0.200nMAssay Description:Inhibition of SMO-mediated hedgehog signalling pathway in human HPEM cells by luciferase reporter gene assayMore data for this Ligand-Target Pair
Affinity DataIC50: 0.400nMAssay Description:Inhibition of SMO-mediated hedgehog signalling pathway in human HPEM cells by luciferase reporter gene assayMore data for this Ligand-Target Pair
Affinity DataIC50: 2.40nMAssay Description:Inhibition of SMO-mediated hedgehog signalling pathway in human HPEM cells by luciferase reporter gene assayMore data for this Ligand-Target Pair
Affinity DataIC50: 2.40nMAssay Description:Inhibition of Smo expressed in mouse NIH/3T3 cells after 20 hrs by Gli reporter gene assayMore data for this Ligand-Target Pair
Affinity DataIC50: 2.60nMAssay Description:Inhibition of Smo expressed in mouse NIH/3T3 cells after 20 hrs by Gli reporter gene assayMore data for this Ligand-Target Pair
Affinity DataIC50: 2.90nMAssay Description:Inhibition of Bcl6 (unknown origin) by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of recombinant full length human N-terminal GST-fused CDK9 (1 to 372 residues)/His-tagged CyclinT1 (1 to 726 residues) expressed in baculo...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Inhibition of CDK9 (unknown origin) using FITC-X-GSRTPMY-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after ...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Inhibition of CDK9 (unknown origin) using FITC-X-GSRTPMY-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after ...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Inhibition of recombinant full length human N-terminal GST-fused CDK9 (1 to 372 residues)/His-tagged CyclinT1 (1 to 726 residues) expressed in baculo...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Inhibition of CDK9 (unknown origin) using FITC-X-GSRTPMY-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after ...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Inhibition of CDK9 (unknown origin) using FITC-X-GSRTPMY-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after ...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Inhibition of CDK9 (unknown origin) using FITC-X-GSRTPMY-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after ...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Inhibition of CDK9 (unknown origin) using FITC-X-GSRTPMY-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after ...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Inhibition of CDK9 (unknown origin) using FITC-X-GSRTPMY-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after ...More data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of cIAP1 BIR3 domain (unknown origin) by fluorescence polarization assayMore data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of cIAP1 BIR3 domain (unknown origin) by fluorescence polarization assayMore data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Inhibition of CDK9 (unknown origin) using FITC-X-GSRTPMY-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after ...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Inhibition of CDK9 (unknown origin) using FITC-X-GSRTPMY-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after ...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Inhibition of CDK9 (unknown origin) using FITC-X-GSRTPMY-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after ...More data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:Inhibition of recombinant full length human N-terminal GST-fused CDK9 (1 to 372 residues)/His-tagged CyclinT1 (1 to 726 residues) expressed in baculo...More data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:Inhibition of XIAP BIR3 domain (unknown origin) by fluorescence polarization assayMore data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:Inhibition of XIAP BIR3 domain (unknown origin) by fluorescence polarization assayMore data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:Inhibition of CDK9 (unknown origin) using FITC-X-GSRTPMY-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after ...More data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:Inhibition of CDK9 (unknown origin) using FITC-X-GSRTPMY-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after ...More data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:Inhibition of CDK9 (unknown origin) using FITC-X-GSRTPMY-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after ...More data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:Inhibition of human PIM3 using FITC-(AHX)RSRHSSYPAGT-COOH as substrate after 90 mins by mobility shift assay in presence of 50 uM ATPMore data for this Ligand-Target Pair
Affinity DataIC50: <4nMAssay Description:Inhibition of recombinant full length human N-terminal GST-fused CDK9 (1 to 372 residues)/His-tagged CyclinT1 (1 to 726 residues) expressed in baculo...More data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:Inhibition of human PIM1 using FITC-(AHX)RSRHSSYPAGT-COOH as substrate after 90 mins by mobility shift assay in presence of 5 mM ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:Inhibition of Smo expressed in mouse NIH/3T3 cells after 20 hrs by Gli reporter gene assayMore data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:Inhibition of CHK1 (unknown origin)More data for this Ligand-Target Pair